Hikma Pharmaceuticals : Director/PDMR Shareholding

1.

Name of the issuer

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

SAID DARWAZAH

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

3 ABOVE

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

ORDINARY SHARES OF 10P EACH

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

8.

State the nature of the transaction

PURCHASE OF 150,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

150,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.06%

11.

Number of shares, debentures or financial

instruments relating to shares disposed

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

N/A

13.

Price per share or value of transaction

£22.00p

14.

Date and place of transaction

24 JUNE 2016, LONDON

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

13,313,161 (5.56%) COMPRISING:

DIRECTLY, INCLUDING CONNECTED PERSONS: 745,383 (0.31%)

INDIRECTLY THROUGH DARHOLD LIMITED: 12,567,778 (5.25%)

16.

Date issuer informed of transaction

24 JUNE 2016

17.

Date of grant

N/A

18.

Period during which or date on which exercisable

N/A

19.

Total amount paid (if any) for grant of the option

N/A

20.

Description of shares or debentures involved (class and number)

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

N/A

22.

Total number of shares or debentures over which options held following notification

N/A

23.

Any additional information

N/A

24.

Name of contact and telephone number for queries

PETER SPEIRS 0207 399 2772

Name of authorised official of issuer responsible for making notification

Peter Speirs, Company Secretary

Date of notification 27 June 2016

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

1.

Name of the issuer

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

MAZEN DARWAZAH

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

3 ABOVE

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

ORDINARY SHARES OF 10P EACH

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

8.

State the nature of the transaction

PURCHASE OF 150,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

150,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.06%

11.

Number of shares, debentures or financial

instruments relating to shares disposed

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

N/A

13.

Price per share or value of transaction

£22.00p

14.

Date and place of transaction

24 JUNE 2016, LONDON

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

7,279,931 (3.04%) COMPRISING:

DIRECTLY: 952,965 (0.40%)

INDIRECTLY THROUGH DARHOLD LIMITED: 6,326,966 (2.64%)

16.

Date issuer informed of transaction

24 JUNE 2016

17.

Date of grant

N/A

18.

Period during which or date on which exercisable

N/A

19.

Total amount paid (if any) for grant of the option

N/A

20.

Description of shares or debentures involved (class and number)

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

N/A

22.

Total number of shares or debentures over which options held following notification

N/A

23.

Any additional information

N/A

24.

Name of contact and telephone number for queries

PETER SPEIRS 0207 399 2772

Name of authorised official of issuer responsible for making notification

Peter Speirs, Company Secretary

Date of notification 27 June 2016

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

1.

Name of the issuer

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

MOHAMMED 'ALI' AL-HUSRY

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

3 ABOVE

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

ORDINARY SHARES OF 10P EACH

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

8.

State the nature of the transaction

PURCHASE OF 150,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

150,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.06%

11.

Number of shares, debentures or financial

instruments relating to shares disposed

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

N/A

13.

Price per share or value of transaction

£22.00p

14.

Date and place of transaction

24 JUNE 2016, LONDON

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

5,814,166 (2.43%) UNDER DYKB LIMITED COMPRISING:

DIRECTLY: 1,162,811 (0.49%)

INDIRECTLY THROUGH DARHOLD LIMITED: 4,651,355 (1.94%)

16.

Date issuer informed of transaction

24 JUNE 2016

17.

Date of grant

N/A

18.

Period during which or date on which exercisable

N/A

19.

Total amount paid (if any) for grant of the option

N/A

20.

Description of shares or debentures involved (class and number)

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

N/A

22.

Total number of shares or debentures over which options held following notification

N/A

23.

Any additional information

N/A

24.

Name of contact and telephone number for queries

PETER SPEIRS 0207 399 2772

Name of authorised official of issuer responsible for making notification

Peter Speirs, Company Secretary

Date of notification 27 June 2016

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.